Hepcvir L
HEPCVIR-L is a fixed-dose combination (FDC) of ledipasvir and sofosbuvir, which are direct-acting antiviral agents against the hepatitis C virus (HCV)
Description
Ledipasvir is an inhibitor of the HCV NS5A protein, which is required for viral replication. Sofosbuvir is an inhibitor of the HCV NS5B RNA-dependent RNA polymerase, which is required for viral replication. Sofosbuvir is a nucleotide prodrug that undergoes intracellular metabolism to form the pharmacologically active uridine analog triphosphate (GS-461203), which can be incorporated into HCV RNA by the NS5B polymerase and acts as a chain terminator.
Features:
- Name : Hepcvir L
- Drud name : Ledipasvir 90 MG & Sofosbuvir 400 MG
Side Effects:
- Headache,Nausea
- Diarrhea
